Abeome granted Millipore an exclusive worldwide license to market and distribute the Human Embryonic Stem Cell Antigen-1 antibody for research use.

In December 2007, EMD Chemicals’ Novagen brand licensed Luminex’s xMAP Technology platform in order to develop immunoassays for it.

Rules-Based Medicine granted EMD Chemicals exclusive distribution rights to its quantitative protein multiplex assays, and the companies will develop immunoassay products for the Luminex xMAP platform for sale under the Novagen name starting in mid-2008.

Invitrogen exclusively licensed cell proliferation assays based on Harvard University’s “click” labeling and detection chemistry for Invitrogen’s Click-iT product line.

Invitrogen exclusively licensed from IMBcom Proprietary, the University of Queensland’s commercialization firm, new noncoding RNA content predicted by a proprietary algorithm for its NCode miRNA microarrays.

Rxi Pharmaceuticals exclusively licensed certain RNAi sequences from Thermo Fisher Scientific.

Promega went direct in Sweden in January.

Cell Genesys sold its lentiviral gene delivery technology to Lentigen for $12 million in cash. Cell Genesys retains rights to use the technology for R&D.

Multispan and Promega will combine their respective GPCR cell lines and bioluminescent technologies to create novel optimized GPCR screening tools.

Fluorotechnics appointed Wako Pure Chemical Industries its Japanese distibutor in January.